Dr. Reddy’s Laboratories Ltd with ticker code (RDY) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 69 and 66.4 calculating the average target price we see 67.7. With the stocks previous close at 50.25 this would indicate that there is a potential upside of 34.7%. The day 50 moving average is 53.63 while the 200 day moving average is 59.99. The market capitalisation for the company is $8,441m. Visit the company website at: https://www.drreddys.com
The potential market cap would be $11,372m based on the market concensus.
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
